Dominion Aesthetic Technologies Inc reported on Tuesday the receipt of US FDA clearance for its medical, non-contact body contouring product, eon FR.
The company added that the eon FR is capable of reducing fat over a larger surface area than its competitors, which is highly desired by both physicians and patients. The body shaping technology delivers non-contact, laser energy to reduce fat in the abdomen using a patent-pending powered articulated arm.
According to the company, the eon FR causes the death of fat cells through apoptosis process that takes from six to 12 weeks and after the eon FR body contouring treatment, the body naturally eliminates fat cells through its lymphatic system. The treatment takes about 15 minutes to perform with no downtime.
Headquartered in San Antonio, TX, the laser-based medical device company offers the best innovative tools to serve the physicians' practices and the patients' needs.
Airiver medical receives FDA approval for central airway stenosis trial
Talphera reaches enrollment milestone in NEPHRO CRRT pivotal trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions